NCT02193815

A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis

A Phase 1, Single- Center, Randomized, Double-blind, Vehicle And Active Comparator-controlled Trial To Evaluate The Antipsoriatic Activity And Safety Of A Topically Applied Pf-06263276 Formulation In A Psoriasis Plaque Test

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a vehicle and comparator controlled Proof of Mechanism (PoM) trial to evaluate the effect on psoriasis disease activity and safety of topically applied PF 06263276 in subjects with psoriasis vulgaris.

Conditions

• Psoriasis Vulgaris

Interventions

Type	Name	Description
DRUG	PF06263276	4% PF 06263276 solution Daily dosage: approximately 8 mg PF 06263276 QD
OTHER	Vehicle	Active ingredient-free vehicle to 4% solution
DRUG	2%Tofacitinib Ointment	Daily Dosage: approximately 4 mg tofacitinib
OTHER	Vehicle	Active ingredient-free vehicle to 2% Ointment
DRUG	Daivonex	Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
DRUG	Daivonex Ointment	Daivonex ointment (50 ug/g Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg

Timeline

• Start date: 2014-09-01
• Primary completion: 2015-02-01
• Completion: 2015-02-01
• First posted: 2014-07-18
• Last updated: 2016-06-09
• Results posted: 2016-06-09

Locations

1 site across 1 country: Germany